Intensity Therapeutics Plunges 46.46% on Public Offering

On June 12, 2025, Intensity Therapeutics, Inc. experienced a significant drop of 46.46% in pre-market trading, marking a substantial decline in its stock value.

Intensity Therapeutics, Inc. has recently announced a proposed public offering of its common stock. The company plans to use the net proceeds from this offering to enroll patients and reach data readout in the INVINCIBLE-4 Study, which is a crucial phase in its clinical trials for cancer immunotherapy.

The public offering includes 6,675,000 shares priced at $0.30 per share. The company has also granted underwriters a 45-day option to purchase additional shares, indicating a strategic move to raise capital for its ongoing research and development efforts.

This public offering is part of Intensity Therapeutics' broader strategy to secure funding for its innovative cancer immunotherapy platform. The company aims to leverage the capital raised to advance its clinical trials and bring its groundbreaking treatments closer to market.